Fosun annual report: revenue of 24.9 billion, pharmaceutical research and investment of more than 2 billion, 215 in research, 29 sales of over 100 million products

On March 27, the 2018 annual report of Fosun Pharmaceutical was published, with revenue of 24.918 billion yuan, a year-on-year increase of 34.45% Among them, the revenue of pharmaceutical manufacturing and R & D business reached 18.681 billion yuan, a year-on-year increase of 41.57%; after excluding the influence of comparable factors such as the contribution of new merger and acquisition enterprises, the revenue of pharmaceutical manufacturing and R & D business in the reporting period increased by 24.87% compared with the same caliber in 2017 During the reporting period, the R & D investment of pharmaceutical business was RMB 2.25 billion, an increase of 76.49% over 2017 The net profit attributable to the shareholders of the listed company was 2.708 billion yuan, a year-on-year decrease of 13.33% During the reporting period of pharmaceutical manufacturing revenue, Fosun Group's pharmaceutical manufacturing and R & D business achieved an operating revenue of 18681.3451 million yuan, an increase of 41.57% compared with that in 2017; after excluding the influence of comparable factors such as the contribution of new merger and acquisition enterprises, the pharmaceutical manufacturing and R & D business revenue in the reporting period increased by 24.87% compared with the same caliber in 2017 In 2018, there are 29 pharmaceutical single products or series with sales of over 100 million in the pharmaceutical sector, including 2 pharmaceutical single products or series with sales of over 1 billion, 7 pharmaceutical single products or series with sales of between 500 million and 1 billion, and 5 Pharmaceutical single products or series with sales of between 300 million and 500 million The sales revenue of core products in main treatment areas is as follows: The core products in the main treatment fields, such as non bustatin (uliton), pivastatin (Bangzhi), quetiapine fumarate (qi14 / 371v), antituberculosis series, vancomycin, enoxaparin injection, alfacalcitol (Liqing), piperacillin sodium and Sulbactam Sodium for injection (qiangshuxilin), have maintained rapid growth Among them, the sales volume of febuxostat, pivastatin, quetiapine fumarate and vancomycin increased by 146%, 213%, 37% and 80%, respectively Drug manufacturing and R & D in 2018, R & D investment in Fosun Pharmaceutical business was 2250472500 yuan, an increase of 975363900 yuan, or 76.49%, compared with 2017, and R & D investment in pharmaceutical business accounted for 12.0% of the pharmaceutical business income; among them, R & D cost was 1255161600 yuan, an increase of 45 yuan compared with 2017, 6.1836 million yuan, up 57.10%, accounting for 6.7% of the pharmaceutical business income Compared with peers, R & D investment is in the upper middle level The increase of R & D investment is mainly due to the increase of R & D investment in bio innovative drugs and bio similar drugs, small molecule innovative drugs, consistency evaluation, and the increase of R & D investment in Innovation Incubation Platform during the reporting period As of the end of the reporting period, Fosun has 215 projects in the research of new drugs, generic drugs, biological similar drugs and generic drug consistency evaluation, including 15 small molecule innovative drugs, 10 biological innovative drugs, 17 biological similar drugs, 117 international standard generic drugs, 54 consistency evaluation projects and 2 traditional Chinese medicines In 2018, Fosun will focus on increasing R & D investment in monoclonal antibody bio innovative drugs, bio similar drugs and small molecule innovative drugs, and systematically promote the development of generic drug consistency evaluation As of the end of the reporting period, 9 small molecule innovative drug products (including 1 improved new drug) and 9 indications have been approved in clinical trials in mainland China; 13 monoclonal antibody products and 1 joint treatment scheme have completed 22 indications of clinical trials and obtained 27 clinical trials worldwide During the reporting period, five generic products of glandpharma were approved by the U.S FDA; nine products, including amlodipine besylate tablets (schlida), escitalopram oxalate tablets (departure) and alfacalcohol tablets (Liqing), passed the generic consistency evaluation As of the end of the reporting period, the research and development progress of monoclonal antibodies is as follows: the specific research and development progress of small molecule chemical innovative drugs is as follows: in addition, there are 99 patent applications in the pharmaceutical sector, including 12 in the United States, 1 in Japan, 2 in Europe, 5 in India and 4 in PCT; 35 patents (all invention patents) have been granted As of the end of the reporting period, the holding subsidiaries of the pharmaceutical business have met the requirements of the new national GMP While the production line meets the requirements of new domestic GMP standards, Fosun actively promotes the internationalization of pharmaceutical enterprises, and encourages enterprises to participate in the implementation of quality system certification such as cGMP in the United States, the European Union, who, etc As of the end of the reporting period, more than 10 APIs of Fosun have passed GMP certification of national health departments such as the US FDA, the European Union, Japan's Ministry of health and the German Health Bureau; 4 preparation production sites and 3 API production sites of glandpharma have passed the drug regulatory audit / certification of the US, Europe and Brazil during the reporting period; 1 solid oral preparation production line and 3 injections of Guilin South pharmaceutical Co., Ltd The production line and 5 APIs passed the who-pq certification inspection; Chongqing Yaoyou has one oral solid preparation production line passed the certification of the Ministry of health of Canada and the FDA of the United States The total sales Investment in 2018 is 8.487 billion yuan, accounting for 34.06% of the revenue, basically consistent with the peers Fosun's market position in 2018, China's pharmaceutical manufacturing industry as a whole is in a period of transformation According to the hospital terminal market data released by iqvia, the industry as a whole keeps growing in 2018, with an average growth rate of about 3.3% According to iqvia statistics, in 2018, the sales revenue of hospital prescription drugs produced by Fosun ranked 10th in China And Fosun has established a mature drug sales network and upstream and downstream customer resources in French speaking countries and regions in Africa, Artemisinin series antimalarial products have been highly recognized by the African market, artesunate for injection has been listed as the first choice for severe malaria treatment; as one of the top three drug distribution companies in the French speaking region of West Africa, tridem Pharma has further consolidated the group's competitiveness in the African market and improved the international marketing network of Fosun drugs In addition, Fosun has also set up marketing platforms in the United States and Europe to promote in-depth cooperation with European and American pharmaceutical companies, and improve Fosun's pharmaceutical sales scale in the international market.